Medical Health & Life Science Research News

Next Generation Antibody Therapeutics Market forecast 2019-2026 interpreted by a new report

Medicine

Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The global next generation antibody therapeutics market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, at a CAGR of XX% during the forecast period (2019-2026).

- Advertising -

Market Overview:

Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases.

The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026.

Market Dynamics:

The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. 

Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease.

- Advertising -

The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA).

The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market.

However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. 

Market Segmentation:

Based on technology, the global next generation antibody therapeutics market is segmented into Bispecific Antibodies (BsAbs), Biosimilar Antibody (Ab) Products, Antibody-Drug Conjugates (ADCs), Fc-engineered Antibodies, Antibody Fragments and Antibody-Like Proteins (AF & ALPs), and others. Among these, ADCs accounted for the largest market share in 2018 and estimated to dominate during the forecast period.

The ADC technology is majorly used for the manufacturing of next-generation antibody therapeutics for treating cancer. The ADCs are manufactured by linking an anti-cancer drug, or another therapeutic agent to an antibody or antibody fragment.

Because of high efficiency delivered by ADCs, various pharmaceutical companies, such as Seattle Genetics Inc., ImmunoGen Inc., F. Hoffmann-La Roche Ltd, and Bristol-Myers Squibb Company are actively involved in the development of next-generation antibody therapeutics using ADC technology.

Based on therapeutic area, next-generation antibody therapeutics market can be segmented into oncology, autoimmune/inflammatory, and others. Among these, the oncology accounted for the largest market share in 2018, due to rising incidence of cancer globally.

For instance, according to the World Health Organization (WHO), cancer accounts for 13% of deaths globally every year. Moreover, a 70% increase in cancer incidences is anticipated over the next couple of decades and the global geriatric population is anticipated to nearly double from 12% to 22%, from 2015 to 2022.

The incidence of all cancer types worldwide is anticipated to increase at a CAGR of 2.5% during 2015-2030.

Get a free sample of the exclusive report now@ www.datamintelligence.com/downloa…ics-market

Geographical Analysis:

North America holds the dominant market share for next generation antibody therapeutics in 2018, and it is expected to maintain the growth over the forecast period, owing to the increasing research & development activities, technological advancement in antibody therapies, rising healthcare expenditure and increasing government initiatives in this region. In addition, rising incidence of chronic diseases, and increasing approvals for new drugs are also driving the growth of the market.

A total of 12 new antibodies were granted approvals in either the US or EU during 2018. Perhaps reflecting the higher approval success rate for antibodies that are treatments for non-cancer indications, the majority (75%) of the products are for such diseases, including 3 for migraine prevention and 1 for human immunodeficiency virus (HIV) infection.

Asia-Pacific next generation antibody therapeutics market is growing at the highest CAGR during the forecast period (2019-2026), due to rising demand from the developing countries such as India and China. The rising incidence of various diseases, increasing improvements in therapeutic antibody, emerging antibody technologies, growing demand for better healthcare facilities and rapid growth in biosimilar antibodies and engineered antibodies are expected to offer new opportunities for next-generation antibody therapeutics market in this region.

Competitive Analysis:

Some of the major players in the global Next Generation Antibody Therapeutics market are: Bayer AG, Amgen Inc., AstraZeneca PLC., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Biogen, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, ImmunoGen Inc., Seattle Genetics Inc., among others.

Enquire more about the report@ www.datamintelligence.com/enquiry…ics-market

View Full Report Sample@ www.datamintelligence.com/researc…ics-market

News From

DataM IntelligenceDataM Intelligence
Category: Market Research Publishers and RetailersCompany about: DataM Intelligence was established on an elemental idea of publishing Advanced Market Research Reports with precise data points & utmost accuracy that will accelerate the decision making in designing disruptive solutionsWe monitor and analyse the market by dissecting various parameters such as market influencers, competitive intensity, innovations, trends, and emerging products. This aids us in providing the detail scenario of the present and future of the market.We have evolved by building ...
This email address is being protected from spambots. You need JavaScript enabled to view it.